Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Thyroid cancer

VEGF

Mouse and human studies suggest Votrient pazopanib, a VEGF signaling inhibitor, could help improve the efficacy of paclitaxel in anaplastic thyroid cancer. In a mouse xenograft model of human anaplastic thyroid cancer, paclitaxel plus Votrient decreased tumor volume compared with either compound alone. In a single patient who had anaplastic thyroid cancer with lung metastases, paclitaxel plus Votrient led to durable regression of metastatic disease. Next steps could include running a clinical trial of the combination in patients with anaplastic thyroid cancer.
GlaxoSmithKline plc markets Votrient to treat renal cell carcinoma (RCC) and advanced soft tissue sarcomas. The drug is in Phase II testing to treat thyroid cancer.

SciBX 6(4); doi:10.1038/scibx.2013.85
Published online Jan. 31, 2013

Unpatented; licensing status not applicable

Isham, C.R. et al. Sci. Transl. Med.; published online Jan. 2, 2013;
doi:10.1126/scitranslmed.3004358
Contact: Keith C. Bible, Mayo Clinic, Rochester, Minn.
e-mail:
bible.keith@mayo.edu